REMD-813

N/A

Report date: 2025/02/19 10:16:09

Base Information

Drug NameREMD-813

Drug Alias NameREMD-813

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionLymphocyte activation gene 3 protein inhibitorsProgrammed cell death protein 1 inhibitors

TargetsLymphocyte activation gene 3 proteinProgrammed cell death protein 1

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesRemd Biotherapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesRemd Biotherapeutics Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A